Human Insulin Drugs Market Share

Statistics for the 2023 & 2024 Human Insulin Drugs market share, created by Mordor Intelligence™ Industry Reports. Human Insulin Drugs share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Market Share of Human Insulin Drugs Industry

The global human insulin market is highly consolidated, with three major manufacturers holding a global market presence and the remaining manufacturers confined to other local or region-specific manufacturers. Mergers and acquisitions that happened between the players in the recent past have helped the companies strengthen their market presence. Eli Lilly and Boehringer Ingelheim have an alliance to develop and commercialize Basaglar (Insulin Glargine). Biocon is developing Insulin Tregopil, an oral prandial insulin tablet, for the treatment of type-1 and type-2 diabetes mellitus. Fast-acting oral insulin could improve postprandial glucose control with reduced side effects and greater adherence, thus holding the promise to transform T1D management. Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, is working to bring the first oral insulin product to market, thus providing a more convenient, effective, and safer method for delivering insulin therapy.

Insulin Market Leaders

  1. Novo Nordisk A/S

  2. Eli Lilly and Company

  3. Sanofi S.A.

  4. Biocon Limited

  5. Pfizer Inc.

*Disclaimer: Major Players sorted in no particular order

Human Insulin Drugs Market Concentration

Insulin Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)